Global Epilepsy Market Is Likely to Grow at A CAGR Value of Around 3.10% By 2028

The global Epilepsy Therapeutics market was worth around USD 10.10 billion in 2021 and is estimated to grow to about USD 12.13 billion by 2028, with a compound annual growth rate (CAGR) of approximately 3.10 percent over the forecast period. The report analyzes the Epilepsy Therapeutics market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Epilepsy Therapeutics market.

Epilepsy is a central nervous system disorder in which the brain activity becomes abnormal, thereby resulting in periods of unusual behavior or seizures, sensations, and sometimes, even loss of awareness. Epilepsy market is growing at a significant rate, due to increasing prevalence of neurological disorders and technological advancements in the treatment of these condition. The high vulnerability of people of all groups to epilepsy has created new avenues for the growth of global epilepsy market. The global epilepsy therapeutics market size is inflating at a high growth rate due to an ever-growing ageing population, increase in research and development activities in developing as well as developed markets during the forecast period. Besides, the rising incidence of higher birth-related injuries, neurological disorders, increasing road traffic injuries, growing disease awareness, and rising patient base in developing countries are the significant factors driving the global Epilepsy drug market

The Epilepsy market dynamics are anticipated to change over the upcoming years owing to the improvement in the diagnosis methodologies leading to specialized multidisciplinary care, increased Research and Development, raising awareness of the disease, incremental healthcare spending across the world since the government took initiatives Rising incidence of brain tumours has also generated a plethora of opportunities for growth within the market. On the other hand, lack of affordability and emergence of epilepsy therapeutic methods in the developing nations are factors expected to obstruct the epilepsy treatment market

The global epilepsy therapeutics market has been segmented based on type, product, end-user, distribution channel, and region. In terms of product, the market has been classified into first generation epilepsy therapeutics, second generation epilepsy therapeutics, and third generation epilepsy therapeutics. The second-generation epilepsy therapeutics segment is expected to hold a significant share of the market. Based on distributional channel, the global epilepsy therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is projected to dominate the global market On the basis of end users, the epilepsy treatment market is segmented into hospitals, clinics, ambulatory surgical centers, home care settings and diagnostic centers.

North America is expected to dominate and account for a prominent share of the global epilepsy market during the forecast period. This is majorly due to high awareness among patient population towards new treatment and higher availability of R & D. During the forecast period, the global market is predicted to rise at a rapid pace, with Asia leading the way, followed by Europe. India and China are predicted to be the Asia Pacific region's fastest expanding epilepsy therapeutics markets. Presence of a large base of geriatric population, governmental initiatives to improve the healthcare sector, are some of the primary driving reasons for the epilepsy therapeutics market in emerging countries.

Key players functioning in the global epilepsy therapeutics market include BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA and Zoogenic Inc.

Recent developments:

• In July 2020, Dr Reddy Laboratories ltd, announced the distribution and Co-promotion agreement with USB S>A for Breviate in India. Britvic is approved for the treatment partial-onset seizures in patient 16 years and older.

Browse the full “Epilepsy Therapeutics Market By Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Others), By Location (Rural and Urban), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecasts 2022 – 2028” Report at https://www.zionmarketresearch.com/report/epilepsy-therapeutics-market

Global Epilepsy Therapeutics market is segmented as follows:

By Types Covered

• Anti-Epileptic Drugs
• Brain Surgery
• Dietary Supplements
• Ketogenic Diet
• Surgical Therapies

By End Users Covered:

• Ambulatory Surgical Centers
• Hospitals& Clinics
• Home Care Settings
• Neurology Centers

By Products Covered:

• First Generation Epilepsy Therapeutics
• Second Generation Epilepsy Therapeutics
•  Third Generation Epilepsy Therapeutics

By Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy-User

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com